A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin

Start Date13 Apr 2026

Sponsor / Collaborator

Hanmi Pharmaceutical Co., Ltd.

NCT06174779

/ CompletedPhase 3

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus

Start Date03 Jan 2024

Sponsor / Collaborator

Hanmi Pharmaceutical Co., Ltd.

NCT03770728

/ TerminatedPhase 3

A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

Primary Objective:
To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone or in combination with sulfonylurea (SU).
Secondary Objectives:
* To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo on glycemic control.
* To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo on body weight.
* To evaluate the safety of once weekly injection of efpeglenatide.

Start Date01 Aug 2019

Sponsor / Collaborator

Sanofi

[+1]

100 Clinical Results associated with Efpeglenatide

100 Translational Medicine associated with Efpeglenatide

100 Patents (Medical) associated with Efpeglenatide

Literatures (Medical) associated with Efpeglenatide

01 Sep 2026·DIABETES OBESITY & METABOLISM

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE ‐O Trial

Article

Author: Sattar, Naveed ; Del Prato, Stefano ; Schwarz, Christine R. ; Kovalova, Tanya ; Lam, Carolyn S. P. ; Pratley, Richard ; Lopes, Renato D. ; Raaschou‐Oddershede, Daniel ; Rosenstock, Julio ; Gerstein, Hertzel C. ; Branch, Kelley R.

ABSTRACT:

Aims:

In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables and biomarkers during the trial might explain the observed reduction in MACE.

Materials and Methods:

Measured variables were considered potential mediators if they were significantly changed by the intervention. The hazard (95% CI) per 1‐unit increase in each time‐updated mediator (change from baseline or updated mean) was estimated using Cox models adjusted for the same variables as in the main AMPLITUDE‐O results. Mediators whose hazard‐ratio CIs excluded 1.0 were then included in the MACE Cox model to estimate how much of efpeglenatide's effect on MACE could be statistically explained by its effect on that mediator in uni‐ and multivariable analyses.

Results:

Change in HbA1c, weight, pulse pressure, LDL cholesterol, urinary albumin: creatinine ratio (UACR), eGFR, heart rate, lipase and amylase were modified by efpeglenatide. Of these, univariable analyses showed that only changes in HbA1c, LDL cholesterol, UACR and amylase accounted for 14%, 11%, 16% and 10%, respectively, of the effect of efpeglenatide on MACE. In the multivariable analysis, LDL cholesterol together with UACR accounted for 29.6% mediation of this effect.

Conclusion:

In this post hoc analysis from the AMPLITUDE‐O trial, changes in LDL cholesterol together with UACR but not weight were estimated to statistically account for a modest portion of the reduction in risk of MACE with efpeglenatide.

01 Aug 2026·DIABETES OBESITY & METABOLISM

The Impact of GLP ‐1‐Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta‐Analysis

Review

Author: Shih, Hong‐Mou ; Tsai, Ming‐Chieh ; Chien, Kuo‐Liong ; Lin, Cheng‐Jui ; Liu, Sung‐Chen ; Chuang, Shih‐Ming

ABSTRACT:

Aims:

To provide updated agent‐level comparative estimates of GLP‐1‐based therapies for cardiovascular outcomes in adults with Type 2 diabetes mellitus (T2DM) using a hazard ratio (HR)‐based systematic review and network meta‐analysis (NMA).

Methods:

PubMed, Cochrane Library and Scopus were searched through December 2025 for randomized controlled trials evaluating GLP‐1‐based therapies in adults with T2DM and reporting time‐to‐event cardiovascular outcomes. Pairwise meta‐analyses and a frequentist random‐effects NMA were performed for all‐cause mortality, cardiovascular mortality, major adverse cardiovascular events (MACE), non‐fatal myocardial infarction (MI) and non‐fatal stroke.

Results:

Fifteen trials involving 97,173 participants were included. In pairwise placebo‐controlled analyses, GLP‐1‐based therapies significantly reduced all‐cause mortality, cardiovascular mortality and MACE. In the NMA, mortality estimates for several agents favoured benefit, although most comparisons were not statistically significant. For MACE, efpeglenatide, albiglutide and injectable semaglutide showed the most favourable comparative profiles. Albiglutide reduced non‐fatal MI versus placebo, whereas non‐fatal stroke estimates were imprecise.

Conclusions:

GLP‐1‐based therapies were associated with an overall favourable cardiovascular profile in T2DM. Pairwise analyses supported class‐level benefit, whereas between‐agent differences were more evident for MACE than for mortality outcomes in the NMA.

01 Aug 2026·Canadian Journal of Diabetes

Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials

Article

Author: Rifai, Mohamed ; Alghzawi, Hamzah M ; Bakr, Hager Mohamed ; Abomohsen, Mustafa ; Friedman, Adam ; Gadelmawla, Ahmed Farid ; Elgendy, Mohamed S ; Idries, Iyad Y

The comparative cardiovascular (CV) efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or high CV risk remain uncertain. PubMed, Embase, Web of Science, Scopus, and CENTRAL were searched from inception to December 20, 2025, for randomized controlled trials. We conducted a frequentist random-effects network meta-analysis and reported risk ratios (RRs) with 95% confidence intervals (CIs). Treatments were ranked using P-scores. Regimens were analyzed as individual agents, including albiglutide, dulaglutide, efpeglenatide, exenatide extended release, ITCA 650, liraglutide, lixisenatide, subcutaneous semaglutide, oral semaglutide, tirzepatide, and placebo. Eleven trials (n=83,215) were included. In the 3-point major adverse CV events (MACE) network (11 trials, 11 regimens), heterogeneity and inconsistency were absent (I²=0%, τ²=0). MACE rate was reduced with subcutaneous semaglutide (RR 0.74, 95% CI 0.58 to 0.94), efpeglenatide (RR 0.76, 95% CI 0.61 to 0.94), and albiglutide (RR 0.79, 95% CI 0.69 to 0.91); tirzepatide, oral semaglutide, liraglutide, and dulaglutide were also significantly reduced compared with placebo. Top ranked were subcutaneous semaglutide (P-score 0.87), efpeglenatide (0.84), and albiglutide (0.80). No regimen significantly reduced all-cause or CV death compared with placebo. Stroke was reduced with tirzepatide (RR 0.71, 95% CI 0.54 to 0.93) and dulaglutide (RR 0.77, 95% CI 0.63 to 0.95) vs placebo. Discontinuation and gastrointestinal discontinuation were higher with subcutaneous semaglutide, oral semaglutide, lixisenatide, and ITCA 650. Several GLP-1-based therapies reduced MACE vs placebo, with 3-point MACE emerging as the most consistent efficacy signal. Overall, these findings support guideline-based use of GLP-1 RAs in high-risk T2D while highlighting the need for individualized treatment selection.

News (Medical) associated with Efpeglenatide

01 Jun 2026

·allsci.com

Lilly licenses Hanmi’s GLP-2 agonist sonefpeglutide in USD 1.26b deal

Eli Lilly (NYSE: LLY) has agreed to pay USD 75 million upfront to license sonefpeglutide, a long-acting GLP-2 receptor agonist biologic, from South Korean drugmaker Hanmi Pharm. Co., Ltd. (KRX: 128940), in a pharmaceutical licensing agreement that could total up to USD 1.26 billion including milestones. The deal grants Lilly exclusive worldwide rights — excluding South Korea — to develop, manufacture, and commercialize the LAPSGLP-2 analog across multiple indications, with Hanmi retaining rights to complete its ongoing global Phase II trial in short bowel syndrome (SBS). Under the agreement, Hanmi is eligible to receive up to USD 1.185 billion in clinical development, regulatory approval, and commercialization milestone payments, in addition to sales-based royalties following product launch. Specific milestone amounts and royalty rates were not disclosed. Deal context Sonefpeglutide is a PEGylated GLP-2 receptor agonist engineered using Hanmi’s proprietary LAPSCOVERY platform, which extends the circulating half-life of peptides and proteins through site-specific conjugation to an aglycosylated immunoglobulin Fc fragment via a non-peptidyl polymer linker. The architecture exploits FcRn-mediated endosomal recycling — the same mechanism that gives IgG antibodies their roughly 21-day half-life — while the aglycosylated Fc eliminates effector functions that would be inappropriate for a non-antibody therapeutic context. GLP-2, the native hormone that sonefpeglutide mimics, has a circulating half-life of approximately seven minutes, making unmodified peptide therapeutics clinically impractical at meaningful dosing intervals. The approved GLP-2 analog teduglutide (Gattex, Takeda) requires daily subcutaneous injection; sonefpeglutide’s extended half-life is designed to enable once-weekly or less frequent dosing, which would represent a meaningful improvement in patient convenience if borne out in Phase III data. GLP-2 receptor activation promotes intestinal mucosal growth, reduces inflammation, and supports repair and regeneration of the intestinal lining — mechanisms with established relevance to SBS, a rare condition in which patients lose absorptive capacity following surgical removal of large portions of the small intestine and often require long-term parenteral nutrition. Hanmi is currently conducting a global Phase II trial in SBS and will complete that study independently; Lilly will lead any additional clinical programs it elects to pursue based on the available nonclinical and clinical data package. Beyond SBS, the press release indicates Lilly intends to explore additional indications, though none were named. The LAPSCOVERY platform has previously generated clinical-stage assets in adjacent metabolic areas — including efpeglenatide, a GLP-1 analog that Hanmi previously licensed to Sanofi and which completed a Phase III cardiovascular outcomes trial, albeit Sanofi pulled out of that molecule’s development in 2020. The deal is the latest in a sequence of licensing agreements Lilly has signed with biotech companies over the past 18 months, reflecting a sustained effort to source external assets across modalities. In May 2025, Lilly signed a USD 415 million licensing agreement with Alchemab Therapeutics for ATLX-1282, a first-in-class neurodegenerative candidate. That same month, South Korea-based Rznomics entered a global licensing agreement with Lilly for RNA-editing therapeutics, and in January 2026, Seamless Therapeutics announced a global research collaboration with Lilly focused on programmable recombinase-based gene therapies for hearing loss. For Lilly, the transaction adds a gastrointestinal rare disease asset to a portfolio historically concentrated in diabetes and obesity. The GLP-2 receptor mechanism is biologically distinct from GLP-1 — sonefpeglutide does not carry the weight-loss or glycemic control profile of Lilly’s tirzepatide franchise — but the intestinotrophic biology has potential applicability beyond SBS to other conditions involving intestinal barrier dysfunction, a space that has attracted increasing clinical interest. Whether Lilly pursues those broader indications will depend on the Phase II SBS data Hanmi is generating, the full package of which Lilly will inherit upon trial completion. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Copyright © 2026. AllSci Corp. All rights reserved.

09 May 2026

·prosciento.com

Congratulations to Hanmi Pharmaceutical Co., Ltd.

ProSciento is proud to support the clinical research and development activities of Hanmi Pharmaceuticals and congratulate Hanmi and Sanofi on their partnership to develop therapeutics addressing diabetes. The licensing agreement announced by Sanofi and Hanmi Pharmaceuticals represents the intent to develop and commercialize Hanmi’s portfolio of three long-acting GLP-1 agonist and basal insulin candidates, including efpeglenatide, a phase 2b GLP-1 agonist with the potential for once-weekly to once-monthly dosing; LAPSInsulin-115, a phase 1 once-weekly insulin; and LAPSInsulin Combo, a preclinical once-weekly fixed-ratio GLP-1 agonist/basal insulin combination of efpeglenatide and LAPSInsulin-115. The three candidates were developed using Hanmi’s proprietary LAPSCOVERY technology. According to the press release, Sanofi will provide Hanmi with an upfront payment of €400 million (~$434 million). Hanmi will also be eligible for up to €3.5 billion (~$3.8 billion) based on development, registration, and sales milestones and will earn double-digit royalties on net sales of the products. While Sanofi gains worldwide commercialization rights, Hanmi will retain an exclusive option to co-commercialize the products in South Korea and China. ProSciento and Hanmi have jointly presented data at the American Diabetes Association (ADA) Scientific Sessions and European Association for the Study of Diabetes (EASD) Annual Meetings since 2013. Below are links to abstracts related to the three long-acting GLP-1 agonist and basal insulin candidates and presented at the most recent ADA Scientific Sessions. 96-OR – Unique Profile of the Weekly Insulin HM12470: Very Slow Onset of Action, Rapid Off-Rate Similar to Insulin, and Absence of Insulin Receptor Downregulation 105-LB – Once-a-Month Treatment with HM11260C Improves Glycemic Control in Type 2 Diabetes (T2DM)—Interim Data from a 16-Week Study 172-OR – Once-Weekly Combination of GLP-1R Agonist and Insulin (HM14220) Offers Improved Glycemic Control and Reduced Weight Gain Risk 278-OR – Dose-Response Improvements in Glycemic Control and Body Weight Reductions with HM11260C, a Once-Weekly GLP-1 Receptor Agonist with Liraglutide as Reference, in Type 2 Diabetes (T2DM) 303-LB – Significant Effects of HM11260C on Body Weight over 20 Weeks in Obese Subjects without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study 1116-P – SuperagonisticMechanism of Increased Glucodynamic and Weight Loss Effects of LAPSCA-Exendin-4 (HM11260C) 1123-P – LAPS-Exendin-4 (HM11260C) Significantly Enhances Insulin Secretion and ß-Cell Responsiveness in Subjects with Type 2 Diabetes Mellitus (T2DM) 2561-PO – Noninferior Delay in Gastric Emptying vs. Liraglutide and Favorable Glucometabolic Profile following Treatment with LAPSExendin-4 (HM11260C) in Subjects with Type 2 Diabetes Mellitus (T2DM)

12 Feb 2026

·endpoints.news

Sanofi’s new CEO Belén Garijo gets frosty reception as Dupixent challenge awaits

The negative reaction to the impending departure of Sanofi CEO Paul Hudson, and Merck KGaA leader Belén Garijo as his replacement, is perhaps surprising given the French company’s muted performance under Hudson’s leadership. Sanofi’s shares fell about 3% in Paris and 4% in New York, a cold shoulder that may simply reflect the scale of the challenge that Garijo faces when she takes the reins in late April. She’ll have less than five years before the company’s immunological juggernaut Dupixent goes generic. Investors are concerned Garijo doesn’t have a track record of delivering R&D productivity at Merck KGaA, Jefferies managing director Michael Leuchten told Endpoints News in an interview. He considers that criticism “a little unfair” because the German conglomerate focused its capital allocation on areas other than pharma. “We thought the negative reaction on share price was harsh and kind of misses some of the nuances of what may be going on here,” Leuchten said. The company’s shares have lost about a quarter of their value in the past year. Garijo and her team will have to find pragmatic ways to extend Dupixent’s exclusivity, which could be possible through patent settlements and building on its joint venture with Regeneron, because there isn’t time to “rebuild an R&D organization from scratch” before Dupixent’s patent expires, Leuchten said. “One scenario that I think is possible is for Sanofi to go and acquire some assets that they fully fund and put those assets into the joint venture,” Leuchten said. Sanofi’s strategic priorities will remain unchanged under Garijo, a company spokesperson told Endpoints in an email. At Merck KGaA, Garijo’s history of dealmaking wasn’t scintillating. The biggest deal the company closed under her leadership was the $3.9 billion SpringWorks acquisition , and the rare cancer drugs Merck KGaA obtained haven’t been particularly lucrative so far. Another aspect driving some of the skepticism is that Garijo has had trouble delivering on promises in the past. In a letter in early 2022, she set out a goal for Merck KGaA known as “25 by 25” — achieving €25 billion ($27 billion) in total sales by 2025. The group won’t report its 2025 earnings until next month, but last October it guided to 2025 net sales between €20.8 billion and €21.4 billion. This missed goal is undeniably partly due to pipeline misfires. The failure of Merck KGaA’s evobrutinib in multiple sclerosis in late 2023 was followed by the cancellation of the pivotal trial of the head and neck cancer drug xevinapant in June 2024, after an interim analysis concluded the study was headed for failure. But Sanofi’s efforts to improve its drug development under Hudson didn’t always go as planned either. In 2019, at the beginning of his tenure as CEO, Hudson highlighted six programs as priorities. Two made it to market, Qfitlia (for hemophilia) and Beyfortus (for respiratory syncytial virus), but the others have either disappointed or failed entirely. Hudson also stopped developing a GLP-1 program for diabetes called efpeglenatide, just as other drugmakers were stepping up development efforts of this mechanism in obesity. There is no guarantee that asset would have gone on to do well, but the decision looks poor in retrospect. Sanofi’s current strategy involves going big on vaccines and investing in deals with a budget of up to €15 billion to spend across four key therapeutic areas: immunology, vaccines, neurology and rare diseases. This seems unlikely to compensate for Dupixent’s loss of exclusivity, since the drug accounted for 36% of Sanofi’s 2025 revenues. It was perhaps Sanofi’s eagerness on immunology that led things to go wrong at the French drugmaker under Hudson in the first place, Leuchten said. Sanofi assumed that immunology can be approached rationally and with acceptable risk, but time has shown that the space is “a lot more complicated than we thought,” Leuchten said. “The placebo response rates are all over the shop, you get intratrial variability, so the rational approach doesn’t work as well as anybody thought.” Sanofi’s change at the top seems to have happened fast; CEO transitions can be planned around a year in advance in the normal run of things. But Sanofi has ousted leaders with unceremonious haste before. In 2014 it sacked then-CEO Chris Viehbacher after a boardroom clash over Viehbacher’s management style.

Executive Change

100 Deals associated with Efpeglenatide

External Link

KEGG	Wiki	ATC	Drug Bank
D11947	-	-	DB15650

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 3	South Korea	Hanmi Pharmaceutical Co., Ltd.	03 Jan 2024
Diabetes Mellitus, Type 2	Phase 3	United States	Hanmi Pharmaceutical Co., Ltd.	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	United States	Sanofi	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Germany	Hanmi Pharmaceutical Co., Ltd.	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Germany	Sanofi	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Poland	Sanofi	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Poland	Hanmi Pharmaceutical Co., Ltd.	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Ukraine	Hanmi Pharmaceutical Co., Ltd.	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Ukraine	Sanofi	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	United Kingdom	Sanofi	05 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03496298 (AMPLITUDE-O, Pubmed \| Circulation)	Phase 3	Diabetes Mellitus, Type 2	4,076	Placebo	tayoimiajt(xpyzvuklbd) = wckedoedto kbptuvonzk (soaxuaupfl )	-	20 Feb 2023
				Efpeglenatide 4 mg	tayoimiajt(xpyzvuklbd) = nxbpiuabbf kbptuvonzk (soaxuaupfl )
NCT03353350 (AMPLITUDE-M, Pubmed)	Phase 3	Diabetes Mellitus, Type 2	406	Efpeglenatide 2 mg	wzgjynnoii(lhqoqwvpkv) = btlnonjfvc gecqzgsyjn (snyktkuapa )	Positive	07 Jun 2022
				Efpeglenatide 4 mg	wzgjynnoii(lhqoqwvpkv) = smrhcquksv gecqzgsyjn (snyktkuapa )
NCT03353350 (AMPLITUDE-M, CTgov)	Phase 3	Diabetes Mellitus, Type 2	406	placebo (Placebo)	tyfvhvqgzc(zjijkavbwu) = powqxdcuhv kmujgpzwbc (zzrqwgrtah, 1.16) View more	-	18 Jan 2022
				efpeglenatide (SAR439977) (Efpeglenatide 4 mg)	tyfvhvqgzc(zjijkavbwu) = dhpccmbbkp kmujgpzwbc (zzrqwgrtah, 1.01) View more
NCT03713684 (AMPLITUDE-L, CTgov)	Phase 3	Diabetes Mellitus, Type 2	370	Background therapy (Placebo)	qdugkevscz(lhjonclarf) = gnsvkxvywb xhmqgjfwrc (oztsrplesi, 1.09) View more	-	02 Dec 2021
				Background therapy+Efpeglenatide SAR439977 (Efpeglenatide 2 mg)	qdugkevscz(lhjonclarf) = rkgefqgsxl xhmqgjfwrc (oztsrplesi, 0.95) View more
NCT03770728 (AMPLITUDE-S, CTgov)	Phase 3	Diabetes Mellitus, Type 2	312	Placebo+Metformin (Placebo)	tuihkzvfki(ibdolrkslu) = liayzjbgyd dkswyhyyao (spkdjnwyrn, 0.92) View more	-	02 Dec 2021
				Metformin+Efpeglenatide SAR439977 (Efpeglenatide 2 mg)	tuihkzvfki(ibdolrkslu) = spyyjuyupu dkswyhyyao (spkdjnwyrn, 0.88) View more
NCT03684642 (AMPLITUDE-D, CTgov)	Phase 3	Diabetes Mellitus, Type 2	908	Metformin+Efpeglenatide (Efpeglenatide 4 mg)	bgurnlaysp(bvikikxybm) = vnpwblgpka lfrbvpwxlj (fjtppoktxv, 0.06) View more	-	01 Nov 2021
				Metformin+Efpeglenatide (Efpeglenatide 6 mg)	bgurnlaysp(bvikikxybm) = tslixmfrlt lfrbvpwxlj (fjtppoktxv, 0.06) View more
NCT03496298 (AMPLITUDE-O, CTgov)	Phase 3	Diabetes Mellitus, Type 2	4,076	Placebo (Placebo)	tldjmqomkt = uowjlehtew yvdnfzoyhl (vgvtsxantl, vigtnwsbjh - nmfufncwau) View more	-	15 Oct 2021
				Efpeglenatide (SAR439977) (Efpeglenatide 4 mg)	fcpgdnssfa(eegacuithv) = atfefbnemt idumlcxvec (crfxuzjgjp, uxmgwycrap - sbghpavbhv) View more
NCT03496298 (AMPLITUDE-O, Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 3	Diabetes Mellitus, Type 2	4,076	efpeglenatide	gwjflycmcd(gasezfeajm) = inehfptwok bchlamisiv (xidyaooqtf ) View more	Positive	02 Sep 2021
				Placebo	gwjflycmcd(gasezfeajm) = qaanpujnmx bchlamisiv (xidyaooqtf ) View more
NCT02075281 (BALANCE 205, EASD2019)	Phase 2	Prediabetic State \| Obesity	295	Efpeglenatide 4 mg QW	xmljqisxuo(xkdrkqhkjx) = syoyjuhoyr fkpwbqtbbm (wlnotgoaiw )	Positive	17 Sep 2019
				Efpeglenatide 6 mg QW	xmljqisxuo(xkdrkqhkjx) = ulvcqozdod fkpwbqtbbm (wlnotgoaiw )
NCT02081118 (EASD2015)	Phase 2	Diabetes Mellitus, Type 2	209	HM11260C 8mg	ncgfjebpby(vgpeihdikt) = oeexclofmr wwsrwbayoj (hatkisqzfd ) View more	Positive	16 Sep 2015
				HM11260C 12mg	ncgfjebpby(vgpeihdikt) = gfwuogavcz wwsrwbayoj (hatkisqzfd ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis